Program
MK-6916
A development code.
Its studies are mostly in Renal Insufficiency, led by Merck.
Furthest: phase 2, since Oct 2, 20264 company-led studies, 3 open or runningNext primary completion: Feb 9, 2027 (phase 1)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Merck | 43 open or running | phase 2since Oct 2, 2026 | Feb 5, 2025 | Feb 9, 2027phase 1 · NCT07862621 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Feb 5, 2025First study: phase 1 study in HealthyFirst studyNCT06818968 · 37 enrolled · United States
- Oct 2, 2026Phase 1 study in HealthyNCT07862621 · 18 planned
- Oct 2, 2026Phase 2 study in AgnosiaPhase 2 reachedNCT07862595 · 380 planned · United States
- Nov 2, 2026Phase 1 study in Renal InsufficiencyNCT07922174 · 32 planned
Ahead
- Feb 9, 2027Primary completion: phase 1 study in HealthyNCT07862621
- Jun 10, 2027Primary completion: phase 2 study in AgnosiaNCT07862595
- Aug 6, 2027Primary completion: phase 1 study in Renal InsufficiencyNCT07922174
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 4 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07922174Renal Insufficiency | 1 | Not yet recruiting | Aug 6, 2027 | 32 |
| NCT07862621Healthy | 1 | Not yet recruiting | Feb 9, 2027 | 18 |
| NCT07862595Agnosia · United States | 2 | Not yet recruiting | Jun 10, 2027 | 380 |
| NCT06818968Healthy · United States | 1 | Completed | Aug 8, 2025 | 37 |
How it is read
Names in the registry
- “MK-6916”, 4 entries
Codes read as this program: MK6916.
Conditions, from the studies’ own filings
- Renal Insufficiency, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.